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UK; 2UK Cystic Fibrosis Gene Therapy Consortium, Edinburgh/London/Oxford, 
UK 
There is a need for clinical endpoint assays for CFGT (Griesenbach and Boyd, 
J. Cyst. Fibros. 4(2), 89 100, 2005). Here, we describe the assessment of candidate 
biomarkers in human nasal brushings by quantitative RT-PCR (QRT-PCR). Using 
current knowledge of the relationships between CFTR and other proteins or 
pathways associated with CF lung pathogenesis, we carefully selected genes both 
from the literature and our microarray studies to test for expression differences 
between asal brushings from 19 CF patients and 19 healthy controls. To overcome 
the difficulties of low RNA yield from nasal samples we used RNA amplification. 
This also facilitated analysis of many more genes in the same samples than would 
normally be possible using unamplified RNA. QRT-PCR was performed using 
TaqMan as this highly sensitive platform is particularly suited to identifying small 
changes in gene expression. We examined 28 genes, including lactotransferrin 
(LTF), IL-8 (IL8), iNOS (NOS2), calgranulins A and B ($100A8 and $100A9), 
prostaglandin E receptor 4 (PTGER4), uteroglobin (SCGB1A1), chemokine ligand 
2 (CXCL2) and CFTR itselfi Of these, 6 were found to be significant, including 
LTF, PTGER4 and CXCL2 (~>2-fold, p < 0.05). We have also designed assays to 
examine CFTR-interacting proteins and will present mRNA expression data on 
these genes. 
In conclusion, we have found a subset of CF-associated genes that show differences 
in mRNA abundance between CF patient and control nasal epithelium. By ranking 
significantly differentially regulated genes we aim to identify the most robust 
candidate markers to be taken forward as point assays for pre-clinical and clinical 
CFGT trials. 
3. New therapies' 
Whole Body Vibration - a new therapeutic approach to improve 
muscle function in CF? 
S. van Koifingsbruggen 1 , O. Senfler 2, E. Schoenau 2, E. Rietschel 1 . 1 CF-Center, 2Department of 
Pediatric Endocrinology, University of Cologne, Germany 
Disease progression i  CF leads to muscle wasting and loss of muscle function. 
Aim of the study was to evaluate he effects of whole body vibration on muscle performance in adult 
CF-patients. 
Methods: 10 patients aged 24~46 years (3 m; 7 f) have completed the 3 months' study. FEV 1 was 
16 108% predicted (48±28) and BMI 15.4~4.4kg/m 2 (19.5±2.7). 
Whole body vibration was provided by an oscillating board (Galileo 2000). The patients were standing 
in an upright position receiving vertical vibration of frequencies between 25 and 28 Hz. The vibration 
exercise vokes muscle contractions via stretch reflexes improving muscular activity. The training 
schedule consisted of three 3-minute sessions twice a day 5 days per week for 3 months. 
FEV1, BMI and a test programme with the analysis of muscle function including the chair-rising- 
test were assessed every 4 weeks. Muscle force was measured with the Leonardo Plalfonn being 
calculated by deformation fdetectors which is proportional tothe applied force. The Study has been 
approved by the local ethics con~tfitlee. 
Results: 
patient FEV 1 (%) BMI (kg/ln 2) Chair ising (sec) Max. force RaiseUp/kg (N/kg) 
0 In 3 In 0 In 3 In 0 In 3 In 0 In 3 In 
1 18 19 16.6 16.6 8.8 5.5 15.1 18.2 
2 51 44 21.8 21.8 6.2 5.5 17.1 24.7 
3 42 37 21.1 20.5 7.3 6.9 20.9 23.5 
4 77 85 20.7 21.4 6.1 6.1 20.0 42.9 
5 109 107 24.4 24.4 4.8 4.7 23.5 34.4 
6 42 40 19.7 21.0 6.0 5.5 22.8 29.0 
7 32 35 15.4 16.2 9.2 7.0 
8 21 54 20.7 21.4 7.6 5.1 16.1 35.3 
9 30 28 17.1 16.3 10.8 6.6 13.6 18.8 
10 17 16 17.7 17.9 7.2 8.2 15.0 15.6 
8 of 10 patients showed improvement of muscular performance byreducing their chair-rising time 
and all 9 patients improved in muscle force irrespectively of FEV 1 and BMI. 
Conclusion: These results demonstrate that whole body vibration can improve muscle function in 
CF patients. 
Supported by Wilsing Stifi~lg, Cologne, Germany 
Respiratory syncytial virus prophylaxis in Cystic Fibrosis: 
pilot study 
T.W Prendiville, M.J. Mahony. Mid-Western Regional Hospital, Dooradoyle, 
Ireland 
Background: Presently, there is limited data on the use of  RSV monoclonal 
antibody in children with cystic fibrosis. 
Aim: To assess the efficacy of  palivizumab in the passive immunoprophylaxis 
against RSV infection in three of our CF infants during their first RSV season. 
Methods: 15mg/kg per dose of tim. humanized monoclonal antibody to RSV 
was administered monthly for a maximum of 5 doses from the start of our RSV 
Bronchiolitis eason. A detailed monthly review was performed. Assessments of 
respiratory symptomatology, gastrointestinal issues, medication and dietary history 
were noted. RSV nasopharyngeal spirates were taken when clinically indicated. 
Three of our patients met inclusion criteria during the time period of our study. 
Results: From the beginning of the Bronchiolitis eason in 2004 until spring 2006, 
3 infants diagnosed with cystic fibrosis presented to our service. For the duration 
of  their first winter, all three infants were commenced on immunoprophylaxis to 
RSV All infants tolerated a combined administrative dosing of 13 intramuscular 
injections of  palivizumab well. Despite the winter period of monthly prophylaxis, 
one of the infants presented with RSV-confirmed Bronchiolitis in March 2005 at 
6 months of age having received her third dose of palivizumab 24 days previously. 
The other two infants never presented nor were admitted with either clinical or 
laboratory-confirmed Bronchiolitis. 
Conclusion: A total of 13 doses of intramuscular palivizumab were administered 
and the drug was well tolerated. Two out of the three cystic fibrosis infants under one 
years of  age during their first winter Bronchiolitis eason did not present clinically 
with Bronchiolitis nor tested positive to RSV nasopharyngeal aspirates, suggesting 
a degree of immunity provided by the RSV immunoprophylactic. 
